Skip to content

Late testing rates declining in Europe, but largely in gay men

Future HIV care will include both novel antiretroviral drugs and new treatment strategies

Francois Raffi, of Centre Hospitalier Universitaire in Nantes, speaking at EACS 2013. Photo by Liz Highleyman, hivandhepatitis.com

Dual therapy with Kaletra and 3TC works well regardless of viral load

Pedro Cahn, Fundacion Huesped, Argentina, presents results of the Gardel study at EACS2013. Photo by Liz Highleyman, hivandhepatitis.com

GSK1265744 rapidly suppresses HIV and appears safe at selected dose

David Margolis, Glaxo SmithKline, at EACS 2013. Photo by Liz Highleyman, hivandhepatitis.com

Ensuring good-quality HIV care in Europe: where can we improve?

Professor Jens Lundgren, University of Copenhagen. Photo by Liz Highleyman, hivandhepatitis.com

New EACS treatment guidelines strike balance between individual choice and public health, say writers

New EACS treatment guidelines strike balance between individual choice and public health, say writers

CCR5 inhibitor cenicriviroc shows good activity against HIV; new formulation may reduce dropouts

Judith Feinberg of the University of Cincinnati at EACS 2013. Photo by Liz Highleyman / hivandhepatitis.com

Number of people infected with drug-resistant HIV in Europe has risen by around 35%

Experts debate whether HIV cure is 'hype or hope'

The panel at the mock trial at EACS 2013. Photo © Liz Highleyman / hivandhepatitis.com.